LONDON – Glaxosmithkline plc is divesting Strimvelis, the only approved gene therapy in Europe – along with the rest of its rare disease gene therapy portfolio – to privately held Orchard Therapeutics Ltd., in return for a 19.9 percent stake in the London-based startup.